JenaValve Names Dr. Duane Pinto as Chief Medical Officer

JenaValve has named Duane Pinto, MD, MPH as its new chief medical officer.
 
Dr. Pinto joined the company following over 20 years of performing complex coronary, structural, and peripheral vascular procedures with and without circulatory assistance. He was an associate professor of medicine at Harvard Medical School and the chief of the interventional cardiology section at Beth Israel Deaconess Medical Center.
 
Dr. Pinto is also a trained proctor for the newest transcatheter valves and has been invited around the world to advise and perform interventional cardiology procedures.
 
“We are incredibly pleased to welcome Dr. Pinto to the JenaValve team,” John Kilcoyne, CEO told the press. “Dr. Pinto’s vast experience in interventional cardiology will be invaluable as we develop our ongoing clinical and commercialization strategies of the Trilogy Heart Valve System for the treatment of aortic valve diseases. Moreover, his demonstrated commitment to the most critically ill cardiac patients, leadership in advancing structural heart devices and clinical study experience make him an ideal addition to our team.”
 
Through the publication of over 100 original manuscripts, case reports, reviews, editorials, and book chapters, Dr. Pinto has pursued research interests in a wide variety of topics and studies, including outcomes and economic analyses for acute myocardial infarction and unstable angina. He has authored numerous device trials for both coronary and peripheral circulations. In addition, Dr. Pinto serves as a manuscript reviewer for NEJM, JACC, Circulation (AHA), and others and is also on the editorial board of Circulation, CCI, and JACC.
 
Dr. Pinto stated, “I am excited to join an innovative organization that is incredibly focused and dedicated to addressing unmet patient needs in the structural heart space. I look forward to expanding on the great work the team has already done.”